To observe the efficacy and safety of Dengzhan Shengmai Capsule (灯盏生脉胶囊) combined with repeated transcranial magnetic stimulation in the treatment of vascular dementia after cerebral infarction.

A total of 69 patients with vascular dementia after cerebral infarction admitted from May 2021 to December 2023 were included in the study, and the patients were divided into control group and observation group by random number table method. The patients in the control group (34 cases) received conventional clinical treatment plus repeated transcranial magnetic stimulation treatment, and the observation group (35 cases) received combined treatment with Dengzhan Shengmai Capsule on the basis of the treatment in the control group, both groups were treated for 2 months. The efficacy and adverse reactions, the changes in TCM symptom scores, the levels of nerve growth factor (NGF), neuron-specific enolase (NSE) and brain-derived neurotrophic factor (BDNF) and blood flow velocity changes in anterior cerebral artery (ACA), middle cerebral artery (MCA) and posterior cerebral artery (PCA), left and right vertebral artery (VA), and Hasegawa dementia scale (HDS) and Mini-Mental State Examination (MMSE) scores before and after treatment were observed.

The total effective rate of the observation group was higher than that of the control group (P<0.05). No serious adverse reactions were observed in observation group and control group (P>0.05). Traditional Chinese medicine syndrome scores, the levels of NGF, NSE and BDNF, the blood flow velocities of ACA, MCA, PCA and VA, HDS score and MMSE score were not significant between the two groups before treatment (P>0.05). After treatment, the TCM syndrome scores, the levels of NGF, NSE and BDNF, the blood flow velocities of ACA, MCA, PCA and VA, HDS score and MMSE score were significantly improved in both groups. These indexes in the observation group were better than those in the control group (P<0.05).

Dengzhan Shengmai Capsule combined with repeated transcranial magnetic stimulation has good efficacy in the treatment of vascular dementia after cerebral infarction and can improve the symptoms, cognitive function, cerebral blood flow and nerve function of the patients.